BridgeBio’s cardiomyopathy drug, Attruby, has seen its sales scale upward every quarter since receiving FDA approval 15 months ago. The treatment has proven to be a worthy competitor to Pfizer’s Vyndamax franchise, with $146 million in sales in the fourth quarter, representing a 35% sequential increase.
The company’s share price dropped by 15% after Pfizer withdrew its patent for compound tafamidis (Vyndaqel) in Europe, opening up the possibility of generic pricing pressure on Attruby. However, BridgeBio used its earnings presentation to reassure investors about Attruby’s strong launch and provided more evidence of its growing momentum.
As of February 20, 2026, a total of 7,804 prescriptions had been written for Attruby. Analysts from Mizuho Securities calculated that the drug is attracting an average of 161 new patients per week, up from some 143 in January.
For the full year 2025, Attruby generated sales of $362 million, with 40% of that revenue collected in the fourth quarter. BridgeBio’s analysts expect continued growth for Attruby, with worldwide sales projections increasing to $1.02 billion and $3.5 billion by 2026.
BridgeBio CEO Neil Kumar said that his company is confident in Attruby’s clinical profile and market positioning, not just its patent status. He cited other indications, such as pulmonary arterial hypertension, statins, and prostate cancer, where second-to-market drugs continued to grow after losing exclusivity.
The company’s efforts to differentiate Attruby from Pfizer’s tafamidis franchise are expected to provide a shield against generic pricing pressure in Europe. With a superior enthalpic binding mode and better stabilization profile, Attruby is poised for long-term growth despite the potential threat of generics.
Source: https://www.fiercepharma.com/pharma/bridgebios-launch-attruby-accelerates-ceo-says-company-will-rely-its-differentiation